RELA is sufficient to mediate interleukin‐1 repression of androgen receptor expression and activity in an LNCaP disease progression model

Abstract excerpt

Abstract Background The androgen receptor (AR) nuclear transcription factor is a therapeutic target for prostate cancer (PCa). Unfortunately, patients can develop resistance to AR‐targeted therapies and progress to lethal disease, underscoring the importance of understanding the molecular mechanisms that underlie treatment resistance. Inflammation is implicated in PCa initiation and progression and we have...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetic Associations and Epidemiology
• Share to Inflammasome and immune disorders
• Share to Systemic Lupus Erythematosus Research